Baseline Hemostatic Biomarker Assessment Identifies Breast Cancer Patients at High Risk for Venous Thromboembolism During Chemotherapy.

When KRS was adjusted to a cut-off of 2 points, the VTE rate in the low–intermediate-risk group was 8%, compared to 25% in the high-risk group, though this did not reach statistical significance (log-rank = 0.188).

also in 111,027 other papers